Virtus Investment Advisers, Inc. Biotechnology

Virtus Investment Advisers, Inc.

$327 Million
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
KROS Keros Therapeutics, Inc.	$445M	$131,000 0.04% of portfolio	8,342	Q3 2025 Added 21.0%
RVMD Revolution Medicines, Inc.	$5.94B	$129,000 0.04% of portfolio	2,768	Q3 2025 Added 21.03%
ARVN Arvinas, Inc.	$562M	$128,000 0.04% of portfolio	15,031	Q3 2025 Added 21.0%
SRRK Scholar Rock Holding Corp	$1.95B	$127,000 0.04% of portfolio	3,415	Q3 2025 Added 21.01%
GHRS Gh Research PLC	$728M	$126,000 0.04% of portfolio	8,869	Q3 2025 Added 21.01%
NUVL Nuvalent, Inc.	$4.15B	$126,000 0.04% of portfolio	1,461	Q3 2025 Added 21.04%
ANNX Annexon, Inc.	$136M	$125,000 0.04% of portfolio	41,987	Q3 2025 Added 21.01%
VIR Vir Biotechnology, Inc.	$747M	$124,000 0.04% of portfolio	21,798	Q3 2025 Added 21.01%
RCKT Rocket Pharmaceuticals, Inc.	$231M	$120,000 0.04% of portfolio	37,064	Q3 2025 Added 21.01%

EWTX Edgewise Therapeutics, Inc.	$1.44B	$119,000 0.04% of portfolio	7,380	Q3 2025 Added 21.02%
PCVX Vaxcyte, Inc.	$2.87B	$118,000 0.04% of portfolio	3,302	Q3 2025 Added 21.0%
SMMT Summit Therapeutics Inc.	$3.67B	$117,000 0.04% of portfolio	5,644	Q3 2025 Added 21.01%
WVE Wave Life Sciences Ltd.	$600M	$113,000 0.03% of portfolio	15,804	Q3 2025 Added 21.01%
DNLI Denali Therapeutics Inc.	$2.34B	$110,000 0.03% of portfolio	7,624	Q3 2025 Added 21.02%
CVAC Cure Vac N.V.	$990M	$109,000 0.03% of portfolio	20,319	Q3 2025 Added 21.0%
JANX Janux Therapeutics, Inc.	$1.22B	$108,000 0.03% of portfolio	4,452	Q3 2025 Added 21.01%
RXRX Recursion Pharmaceuticals, Inc.	$747M	$107,000 0.03% of portfolio	22,009	Q3 2025 Added 21.01%
RGNX Regenxbio Inc.	$498M	$107,000 0.03% of portfolio	11,155	Q3 2025 Added 21.0%

SLN Silence Therapeutics PLC	$247M	$105,000 0.03% of portfolio	20,374	Q3 2025 Added 21.01%
KALV Kal Vista Pharmaceuticals, Inc.	$328M	$105,000 0.03% of portfolio	8,693	Q3 2025 Added 21.01%
BCYC Bicycle Therapeutics PLC	$192M	$101,000 0.03% of portfolio	13,094	Q3 2025 Added 21.01%
VKTX Viking Therapeutics, Inc.	$3.05B	$101,000 0.03% of portfolio	3,982	Q3 2025 Added 21.03%
ALLO Allogene Therapeutics, Inc.	$177M	$100,000 0.03% of portfolio	81,276	Q3 2025 Added 21.01%
AKRO Akero Therapeutics, Inc.	$2.52B	$100,000 0.03% of portfolio	2,125	Q3 2025 Added 21.01%
DYN Dyne Therapeutics, Inc.	$975M	$99,000 0.03% of portfolio	7,869	Q3 2025 Added 21.01%
NRIX Nurix Therapeutics, Inc.	$603M	$87,000 0.03% of portfolio	9,514	Q3 2025 Added 21.01%
AUTL Autolus Therapeutics PLC	$126M	$86,000 0.03% of portfolio	52,924	Q3 2025 Added 21.01%
TRDA Entrada Therapeutics, Inc.	$266M	$84,000 0.03% of portfolio	14,495	Q3 2025 Added 21.0%
MREO Mereo Biopharma Group PLC	$227M	$81,000 0.02% of portfolio	40,930	Q3 2025 Added 21.01%
CGEM Cullinan Oncology, Inc.	$390M	$75,000 0.02% of portfolio	12,714	Q3 2025 Added 21.02%
ALT Altimmune, Inc.	$204M	$59,000 0.02% of portfolio	15,914	Q3 2025 Added 21.01%
CAPR Capricor Therapeutics, Inc.	$137M	$59,000 0.02% of portfolio	8,163	Q3 2025 Added 21.01%
REPL Replimune Group, Inc.	$443M	$48,000 0.01% of portfolio	11,511	Q3 2025 Added 21.0%
MLTX Moon Lake Immunotherapeutics	$472M	$18,000 0.01% of portfolio	2,585	Q3 2025 Added 21.02%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Investment Advisers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Virtus Investment Advisers, Inc. with notifications on news.